Mylan NV (NASDAQ:MYL) has earned an average rating of “Buy” from the twenty-two analysts that are covering the firm, Analyst Ratings Net reports. Seven equities research analysts have rated the stock with a hold recommendation, thirteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $63.14.

Shares of Mylan NV (NASDAQ:MYL) opened at 53.11 on Tuesday. The company has a market cap of $26.12 billion and a PE ratio of 29.59. The stock has a 50 day moving average of $52.44 and a 200-day moving average of $51.45. Mylan NV has a 12 month low of $37.59 and a 12 month high of $76.69.

Mylan NV (NASDAQ:MYL) last released its quarterly earnings results on Friday, October 30th. The company reported $1.43 EPS for the quarter, beating analysts’ consensus estimates of $1.38 by $0.05. The company earned $2.71 billion during the quarter, compared to analysts’ expectations of $2.79 billion. During the same period in the previous year, the company posted $1.16 earnings per share. The company’s quarterly revenue was up 30.1% compared to the same quarter last year. Equities analysts forecast that Mylan NV will post $4.33 earnings per share for the current year.

In other Mylan NV news, CFO John D. Sheehan sold 34,579 shares of the firm’s stock in a transaction dated Thursday, December 17th. The stock was sold at an average price of $55.03, for a total value of $1,902,882.37. Following the completion of the transaction, the chief financial officer now owns 171,251 shares in the company, valued at approximately $9,423,942.53. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Several institutional investors have recently made changes to their positions in the stock. MUFG Americas boosted its position in shares of Mylan NV by 48.7% in the third quarter. MUFG Americas now owns 3,054 shares of the company’s stock worth $123,000 after buying an additional 1,000 shares in the last quarter. Harvest Management purchased a new position in shares of Mylan NV during the third quarter worth $403,000. Jacobs & Company purchased a new position in shares of Mylan NV during the fourth quarter worth $449,000. Quantitative Systematic Strategies boosted its position in shares of Mylan NV by 31.0% in the fourth quarter. Quantitative Systematic Strategies now owns 13,012 shares of the company’s stock worth $710,000 after buying an additional 3,077 shares in the last quarter. Finally, Banced Corp boosted its position in shares of Mylan NV by 36.7% in the fourth quarter. Banced Corp now owns 15,478 shares of the company’s stock worth $837,000 after buying an additional 4,157 shares in the last quarter.

A number of equities research analysts recently commented on MYL shares. Zacks Investment Research raised Mylan NV from a “hold” rating to a “buy” rating and set a $56.00 price target for the company in a research report on Monday, January 18th. Vetr raised Mylan NV from a “hold” rating to a “buy” rating and set a $53.15 price target for the company in a research report on Monday, January 11th. BMO Capital Markets lowered their price target on Mylan NV to $46.00 and set a “market perform” rating for the company in a research report on Monday, November 16th. Guggenheim reissued a “hold” rating on shares of Mylan NV in a research report on Sunday, November 1st. Finally, Citigroup Inc. raised Mylan NV from a “neutral” rating to a “buy” rating in a research report on Friday, November 13th.

Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Company’s generic pharmaceutical business is conducted primarily in the United States and Canada (NASDAQ:MYL); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Company’s API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.

12 Month Chart for NASDAQ:MYL

Receive News & Ratings for Mylan NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan NV and related companies with MarketBeat.com's FREE daily email newsletter.